Tarsus Pharmaceuticals Stock Debt To Equity
| TARS Stock | USD 49.91 0.36 0.73% |
Tarsus Pharmaceuticals fundamentals help investors to digest information that contributes to Tarsus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tarsus Stock. The fundamental analysis module provides a way to measure Tarsus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tarsus Pharmaceuticals stock.
Tarsus |
Tarsus Pharmaceuticals Company Debt To Equity Analysis
Tarsus Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Tarsus Pharmaceuticals Debt To Equity | 0.09 % |
Most of Tarsus Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tarsus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Tarsus Pharmaceuticals has a Debt To Equity of 0.091%. This is 99.83% lower than that of the Pharmaceuticals sector and 99.53% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.81% higher than that of the company.
Tarsus Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics of similar companies.Tarsus Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Tarsus Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 1.82 B | ||||
| Shares Outstanding | 41.19 M | ||||
| Shares Owned By Insiders | 8.04 % | ||||
| Shares Owned By Institutions | 91.96 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Book | 9.09 X | ||||
| Price To Sales | 11.15 X | ||||
| Revenue | 182.95 M | ||||
| Gross Profit | 116.74 M | ||||
| EBITDA | (106.88 M) | ||||
| Net Income | (115.55 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 72.45 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 5.86 X | ||||
| Cash Flow From Operations | (83.03 M) | ||||
| Short Ratio | 12.56 X | ||||
| Earnings Per Share | (3.07) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 69.44 | ||||
| Number Of Employees | 323 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 2.04 B | ||||
| Total Asset | 376.99 M | ||||
| Retained Earnings | (360.21 M) | ||||
| Working Capital | 276.09 M | ||||
| Net Asset | 376.99 M |
About Tarsus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.